568PA phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy. (23rd October 2018) - Beom, S-H; Lee, K-W; Cho, S-H; Park, Y S; Kim, T W; Lee, K H; Jung, M; Shin, S J; Ahn, J B